STAND. COM. REP. NO. 492

Honolulu, Hawaii

RE:    S.B. No. 1487

       S.D. 1

Honorable Colleen Hanabusa

President of the Senate

Twenty-Fourth State Legislature

Regular Session of 2007

State of Hawaii

Madam:

     Your Committee on Health, to which was referred S.B. No. 1487 entitled:

"A BILL FOR AN ACT RELATING TO CONTROLLED SUBSTANCES,"

begs leave to report as follows:

     The purpose of this measure is to amend Hawaii's controlled substance schedules to conform to changes made in federal law.

     Specifically, this measure clarifies the definition of schedule II depressants and adds pregabalin as a schedule V depressant.

     Your Committee received testimony in support of this measure from the Department of Public Safety.

     Your Committee finds that the Hawaii controlled substances schedule II and schedule V need to be updated to conform to federal laws.  Your Committee further finds that the Federal Combat Methamphetamine Epidemic Act of 2005 did not exempt liquid and gel capsule forms of pseudoephedrine products from the reporting and recording requirements.

     Accordingly, your Committee amended this measure by removing the exemption of pseudoephedrine products in liquid, liquid capsule, or gel capsule form from the reporting and record keeping requirement.

     Your Committee further amended this measure by making technical, nonsubstantive changes for the purposes of clarity, consistency, and style.

     As affirmed by the record of votes of the members of your Committee on Health that is attached to this report, your Committee is in accord with the intent and purpose of S.B. No. 1487, as amended herein, and recommends that it pass Second Reading in the form attached hereto as S.B. No. 1487, S.D. 1, and be referred to the Committee on Judiciary and Labor.

Respectfully submitted on behalf of the members of the Committee on Health,

____________________________

DAVID Y. IGE, Chair